On Fri, Sep 13, 2019 at 5:33 PM Heather Morrison < heather.morri...@uottawa.ca> wrote:
> Peter (or others). > > You refer to pharma companies paying tens of thousands of dollars to > re-use open access works. Can you explain / provide examples? If works are > free-to-read, even with All Rights Reserved copyright, pharma companies and > their researchers can read and benefit from knowledge produced to date to > further knowledge at no cost. > See https://twitter.com/petermurrayrust/status/1172554433202458625?s=20 6000 USD for re-use of figures from an NC Cell article in pharma promotion. This is not "voluntary" I have said quite enough on this. If anyone cares about price-gouging by publishers feel free to re-use my tweet under CC BY. -- "I always retain copyright in my papers, and nothing in any contract I sign with any publisher will override that fact. You should do the same". Peter Murray-Rust Reader Emeritus in Molecular Informatics Unilever Centre, Dept. Of Chemistry University of Cambridge CB2 1EW, UK +44-1223-763069
_______________________________________________ GOAL mailing list GOAL@eprints.org http://mailman.ecs.soton.ac.uk/mailman/listinfo/goal